Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CTSD | P07339 | 4/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933017 | 1.00 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9882653 | 1.00 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9932605 | 1.00 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9882438 | 1.00 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9932694 | 0.93 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9932592 | 0.93 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL10279472 | 0.93 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9931429 | 0.93 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9931382 | 0.93 | BACE1 (1.00) | BACE1CYP2D6CTSD | |
| SCHEMBL9931383 | 0.93 | BACE1 (1.00) | BACE1CYP2D6CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | BACE1 1/4885CYP2D6 4201/4885CTSD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.